One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection

被引:27
作者
Van Zanten, SV
Machado, S
Lee, J
机构
[1] Dalhousie Univ, Div Gastroenterol, Queen Elizabeth II Hlth Sci Ctr, Dept Med, Halifax, NS B3H 2Y9, Canada
[2] AstraZeneca Canada Inc, Mississauga, ON, Canada
关键词
D O I
10.1046/j.1365-2036.2003.01554.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: To compare the eradication rates of treatment with esomeprazole, metronidazole and clarithromycin (EMC) vs. omeprazole, metronidazole and clarithromycin (OMC), given for 7 days. OMC treatment was followed by 3 weeks of treatment with 20 mg omeprazole alone; the EMC group received placebo. Methods: A randomized, double-blind, controlled study was conducted in 36 Canadian centres. Patients had a minimum 3-month history of dyspepsia, with or without a previous history of peptic ulcer disease, and were Helicobacter pylori positive by urea breath test. The eradication of H. pylori was determined by two negative breath tests performed at least 4 and 8 weeks following the completion of treatment. Results: The intention-to-treat and per protocol populations consisted of 379 and 339 patients, respectively. The success rates of EMC/placebo were 76% (144/190) by intention-to-treat and 80% (138/172) by per protocol analysis; for OMC/omeprazole, the rates were 72% (137/189) and 75% (125/167), respectively. The difference between the two treatment groups was not significant. Treatment was well tolerated. Conclusions: A 7-day regimen of esomeprazole, metronidazole and clarithromycin is effective and well tolerated for the eradication of H. pylori infection.
引用
收藏
页码:1381 / 1387
页数:7
相关论文
共 22 条
[1]   Helicobacter pylori: Primary susceptibility to clarithromycin in vitro in Nova Scotia [J].
Best, LM ;
Haldane, DJM ;
Bezanson, GS ;
vanZanten, SJOV .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1997, 11 (04) :298-300
[2]  
BEST LM, 1998, CAN J GASTROENTEROL, V12, pA106
[3]  
Calvet X, 2000, ALIMENT PHARM THER, V14, P603
[4]   Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia:: the Canadian adult dyspepsia empiric treatment -: Helicobacter pylori positive (CADET-Hp) randomised controlled trial [J].
Chiba, N ;
van Zanten, SJOV ;
Sinclair, P ;
Ferguson, RA ;
Escobedo, S ;
Grace, E .
BRITISH MEDICAL JOURNAL, 2002, 324 (7344) :1012-+
[5]   Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada [J].
Fallone, CA .
CANADIAN JOURNAL OF GASTROENTEROLOGY, 2000, 14 (10) :879-882
[6]   Sources of variation of Helicobacter pylori treatment success in adults worldwide:: a meta-analysis [J].
Fischbach, LA ;
Goodman, KJ ;
Feldman, M ;
Aragaki, C .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (01) :128-139
[7]   Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole:: a meta-analysis of eradication of Helicobacter pylori [J].
Gisbert, JP ;
González, L ;
Calvet, X ;
García, N ;
López, T ;
Roqué, M ;
Gabriel, R ;
Pajares, JM .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1319-1328
[8]   Risks and benefits of Helicobacter pylori eradication:: Current status [J].
Hunt, RH ;
Fallone, C ;
van Zanten, SV ;
Sherman, P ;
Smaill, F ;
Thomson, ABR .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 16 (01) :57-62
[9]   Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial [J].
Kahrilas, PJ ;
Falk, GW ;
Johnson, DA ;
Schmitt, C ;
Collins, DW ;
Whipple, J ;
D'Amico, D ;
Hamelin, B ;
Joelsson, B .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1249-1258
[10]  
Laheij RJF, 1999, ALIMENT PHARM THERAP, V13, P857